The Takeda lysine-specific demethylase 1 (LSD1) inhibitor (TAK-418) is an oral CNS-penetrant clinical candidate for neurodevelopmental disorders such as autism spectrum disorder. We previously highlighted irreversible and reversible LSD1…
Home > TAK-418
this content is exclusive to
Premium members
Unlock this content with a Premium membership to read it now.